巴比替尼治疗斑秃的疗效综述

S. Alenazi, Mutaib A. Altamimi
{"title":"巴比替尼治疗斑秃的疗效综述","authors":"S. Alenazi, Mutaib A. Altamimi","doi":"10.18203/issn.2455-4529.intjresdermatol20231172","DOIUrl":null,"url":null,"abstract":"Alopecia areata (AA) is a long-term autoimmune condition characterized by patchy, non-scarring hair loss. It involves an autoimmune inflammatory process that gives immunity privilege to some hair follicles, while subsequent inflammatory attacks target previously normal hair follicles. One of the most important discoveries in the pathogenesis of this disease is the Janus kinase (JAK)-signal transducer and activator of the transcription (STAT) pathway. Now that a greater understanding of the immunological processes contributing to the pathogenesis has been gained, current trials’ focus was on managing the immunological reaction involved in this disease. Baricitinib is a new first-generation JAK inhibitor that has been studied in multiple trials. This study's objectives were to review existing research and summarize information on the use of Baricitinib to treat AA. The Medline database was searched for relevant published research papers using variations of the following keywords: “AA,” “Baricitinib,” and “JAK inhibitors.” The search covered studies published from 2010–2022. Our findings showed that baricitinib’s use for severe AA in multiple studies generally led to improvement of patients’ conditions with minimal side effects.","PeriodicalId":14331,"journal":{"name":"International Journal of Research in Dermatology","volume":"25 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Review of efficacy of baricitinib in the treatment of alopecia areata\",\"authors\":\"S. Alenazi, Mutaib A. Altamimi\",\"doi\":\"10.18203/issn.2455-4529.intjresdermatol20231172\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Alopecia areata (AA) is a long-term autoimmune condition characterized by patchy, non-scarring hair loss. It involves an autoimmune inflammatory process that gives immunity privilege to some hair follicles, while subsequent inflammatory attacks target previously normal hair follicles. One of the most important discoveries in the pathogenesis of this disease is the Janus kinase (JAK)-signal transducer and activator of the transcription (STAT) pathway. Now that a greater understanding of the immunological processes contributing to the pathogenesis has been gained, current trials’ focus was on managing the immunological reaction involved in this disease. Baricitinib is a new first-generation JAK inhibitor that has been studied in multiple trials. This study's objectives were to review existing research and summarize information on the use of Baricitinib to treat AA. The Medline database was searched for relevant published research papers using variations of the following keywords: “AA,” “Baricitinib,” and “JAK inhibitors.” The search covered studies published from 2010–2022. Our findings showed that baricitinib’s use for severe AA in multiple studies generally led to improvement of patients’ conditions with minimal side effects.\",\"PeriodicalId\":14331,\"journal\":{\"name\":\"International Journal of Research in Dermatology\",\"volume\":\"25 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Research in Dermatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18203/issn.2455-4529.intjresdermatol20231172\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Research in Dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18203/issn.2455-4529.intjresdermatol20231172","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

斑秃(AA)是一种长期的自身免疫性疾病,其特征是斑驳,无瘢痕性脱发。它涉及一个自身免疫炎症过程,赋予一些毛囊免疫特权,而随后的炎症攻击目标是以前正常的毛囊。在该病发病机制中最重要的发现之一是Janus激酶(JAK)-转录(STAT)途径的信号换能器和激活器。现在对免疫过程对发病机制有了更深入的了解,目前的试验重点是控制与这种疾病有关的免疫反应。Baricitinib是一种新的第一代JAK抑制剂,已在多个试验中进行研究。本研究的目的是回顾现有的研究,并总结使用Baricitinib治疗AA的信息。在Medline数据库中搜索相关已发表的研究论文,使用以下关键词的变体:“AA”、“Baricitinib”和“JAK inhibitors”。该搜索涵盖了2010年至2022年发表的研究。我们的研究结果表明,在多项研究中,baricitinib用于重度AA通常会改善患者的病情,并且副作用最小。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Review of efficacy of baricitinib in the treatment of alopecia areata
Alopecia areata (AA) is a long-term autoimmune condition characterized by patchy, non-scarring hair loss. It involves an autoimmune inflammatory process that gives immunity privilege to some hair follicles, while subsequent inflammatory attacks target previously normal hair follicles. One of the most important discoveries in the pathogenesis of this disease is the Janus kinase (JAK)-signal transducer and activator of the transcription (STAT) pathway. Now that a greater understanding of the immunological processes contributing to the pathogenesis has been gained, current trials’ focus was on managing the immunological reaction involved in this disease. Baricitinib is a new first-generation JAK inhibitor that has been studied in multiple trials. This study's objectives were to review existing research and summarize information on the use of Baricitinib to treat AA. The Medline database was searched for relevant published research papers using variations of the following keywords: “AA,” “Baricitinib,” and “JAK inhibitors.” The search covered studies published from 2010–2022. Our findings showed that baricitinib’s use for severe AA in multiple studies generally led to improvement of patients’ conditions with minimal side effects.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信